[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
Haruka HishikiNaruhiko IshiwadaSachiko NaitoKoo NagasawaTomohiro SomeyaNobue InoueMana HarakiTomomichi KurosakiYousuke KameokaKazuo SuzukiPublished in: The Japanese journal of antibiotics (2016)
We investigated the clinical symptoms of 206 pediatric patients with influenza virus infection and compared them among oseltamivir-treated, zanamivir-treated, and laninamivir-treated groups in 2013/2014 influenza season. The drug compliance of each neuraminidase inhibitor was good in all three groups. Although the duration of fever after administration of the first dose of each neuraminidase inhibitor were significantly prolonged in the patient with influenza B infection than in the patient with influenza A infection, no statistically significant difference in the clinical efficacy and the side effect among three groups were found. The number of biphasic fever episodes in patients treated with neuraminidase inhibitor was rare (two episodes of oseltamivir-treated group and one episode of zanamivir-treated group). In conclusion, under the good drug compliance, the efficacy of all three neuraminidase inhibitor was the same for the treatment of influenza virus infection in children.